Open AccessAmiodarone and optic neuropathy
Author(s) -
Domingues M. F.,
Barros H.,
FalcãoReis F. M.
Publication year - 2004
Publication title -
acta ophthalmologica scandinavica
Language(s) - English
Resource type - Journals
eISSN - 1600-0420
pISSN - 1395-3907
DOI - 10.1111/j.1600-0420.2004.00255.x
Subject(s) - medicine , amiodarone , visual field , ophthalmology , optic neuropathy , audiology , fundus (uterus) , contrast (vision) , visual evoked potentials , optic nerve , optics , physics , atrial fibrillation
. Purpose: To investigate the clinical, perimetric, contrast sensitivity and visual evoked potentials findings in patients on longterm treatment with amiodarone. Methods: We enrolled 14 patients (age range 47–78 years, mean age 62.7 years) on chronic amiodarone therapy (mean cumulative dose of 519 g), and 14 age‐matched control subjects. Participants were submitted to ophthalmological examination, kinetic visual field testing (Goldmann), standard achromatic automated perimetry (central 30–2, Humphrey), computerized isoluminant chromatic contrast sensitivity (CCS) and pattern visual evoked potentials evaluation (VEP). Data from baseline, 6‐month and 1‐year follow‐up examinations were analysed. The main outcome measures were: initial and final corrected visual acuity; corneal, optic disc and fundus abnormalities; mean deviation (MD) and pattern standard deviation (PSD) central 30–2 perimetry parameters; visual field loss on kinetic perimetry; indices of CCS (tritan , protan and deutan axes), and pattern VEP latency (L‐VEP) and VEP amplitude (a‐VEP). Results: We found a statistically significant difference between the patients and controls' baseline L‐VEP and a‐VEP measurements (p < 0.001). We found no significant correlation between prolonged L‐VEP and duration of amiodarone use ( r = 0.07). After a 1‐year follow‐up, we evidenced an average increment in L‐VEP of 1.96 ms and a‐VEP measurements showed a decline of 0.69 µV. In cumulative dose‐specific analyses, mean differences between baseline and 12‐month L‐VEP measurements were more evident in those taking higher than 200 g cumulative amiodarone doses (p = 0.03). We found abnormal tritan CCS results in 19 eyes (68%). Of these, four eyes belonged to patients with no ocular disease (diabetes, cataracts). No significant differences were observed between the baseline and 12‐month clinical eye examinations, central 30–2 perimetry and CCS results. Conclusion: We found a significant prolongation in pattern L‐VEP and a significant reduction in pattern a‐VEP in patients on longterm treatment with amiodarone compared to control subjects. Nevertheless, current data are insufficient to recommend appropriate methods of visual screening.